29.60
+3.33(+12.68%)
Currency In USD
Address
630 West Germantown Pike
Plymouth Meeting, PA 19462
United States of America
Phone
484 539 9800
Sector
Healthcare
Industry
Biotechnology
Employees
268
First IPO Date
August 19, 2020
| Name | Title | Pay | Year Born |
| Dr. Jeffrey M. Dayno M.D. | President, Chief Executive Officer & Director | 1.67M | 1957 |
| Mr. Jeffrey S. Aronin | Founder & Non-Executive Chairman | 40,000 | 1968 |
| Dr. Kumar Budur M.D., M.S. | Executive Vice President and Chief Medical & Scientific Officer | 773,801 | 1971 |
| Mr. Andrew Serafin J.D., M.B.A. | Executive Vice President & Chief Strategy Officer | 791,404 | 1975 |
| Mr. Sandip S. Kapadia CPA, M.B.A. | Executive Vice President, Chief Administrative Officer & Chief Financial Officer | 1.06M | 1970 |
| Ms. Cate McCanless | Senior Vice President & Chief Corporate Affairs Officer | 0 | N/A |
| Brennan Doyle | Vice President & Head of Investor Relations | 0 | N/A |
| Mr. Christian Ulrich J.D. | General Counsel & Corporate Secretary | 0 | N/A |
| Ms. Audrey Murphy SPHR | Chief Human Resources Officer | 0 | N/A |
| Ms. Tricia Glover | Chief Compliance Officer | 0 | N/A |
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
